The human IL-22 receptor is regulated through the action of the novel E3 ligase subunit FBXW12, which functions as an epithelial growth suppressor

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Franz, Joseph ^a   Jerome, Jacob ^b   Lear, Travis ^b   Gong, Qiaoke ^b   Weathington, Nathaniel M ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FBXW12 PROTEIN; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; STAT3 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; F BOX PROTEIN; FBXW12 PROTEIN, HUMAN; INTERLEUKIN-22 RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME DEGRADATION; EPITHELIUM CELL; ESCHERICHIA COLI; FLOW CYTOMETRY; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UBIQUITINATION; CELL CYCLE; CELL LINE; CHEMISTRY; GENE SILENCING; GENETICS; METABOLISM; PROTEIN DOMAIN;

CELL CYCLE; CELL LINE; EPITHELIAL CELLS; F-BOX PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84935023934     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/912713     Document Type: Article

References (27)

1. S. M. Schulz, G. Köhler, N. Schütze et al. , "Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17, " Journal of Immunology, vol. 181, no. 11, pp. 7891-7901, 2008.
2. S. J. Aujla, Y. R. Chan, M. Zheng et al. , "IL-22mediates mucosal host defense against Gram-negative bacterial pneumonia, " Nature Medicine, vol. 14, no. 3, pp. 275-281, 2008.
3. G. F. Sonnenberg, L. A. Fouser, and D. Artis, "Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22, " Nature Immunology, vol. 12, no. 5, pp. 383-390, 2011.
4. S. J. Aujla and J. K. Kolls, "IL-22: a critical mediator in mucosal host defense, " Journal of Molecular Medicine, vol. 87, no. 5, pp. 451-454, 2009.
5. D. Lejeune, L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J.-C. Renauld, "Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct fromIL-10, " Journal of Biological Chemistry, vol. 277, no. 37, pp. 33676-33682, 2002.
6. M.-H. Xie, S. Aggarwal, W.-H. Ho et al. , "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R, " The Journal of Biological Chemistry, vol. 275, no. 40, pp. 31335-31339, 2000.
7. K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat, "IL-22 increases the innate immunity of tissues, " Immunity, vol. 21, no. 2, pp. 241-254, 2004.
8. D. A. Pociask, E. V. Scheller, S. Mandalapu et al. , "IL-22 is essential for lung epithelial repair following influenza infection, " TheAmerican Journal of Pathology, vol. 182, no. 4, pp. 1286-1296, 2013.
9. N. M. Weathington, C. A. Snavely, B. B. Chen, J. Zhao, Y. Zhao, and R. K. Mallampalli, "Glycogen synthase kinase-3 stabilizes the interleukin (IL)-22 receptor from proteasomal degradation in murine lung epithelia, " Journal of Biological Chemistry, vol. 289, no. 25, pp. 17610-17619, 2014.
10. M. H. Glickman and A. Ciechanover, "The ubiquitinproteasome proteolytic pathway: destruction for the sake of construction, " Physiological Reviews, vol. 82, no. 2, pp. 373-428, 2002.
11. T. Ravid and M. Hochstrasser, "Diversity of degradation signals in the ubiquitin-proteasome system, " Nature ReviewsMolecular Cell Biology, vol. 9, no. 9, pp. 679-690, 2008.
12. J. Jin, T. Cardozo, R. C. Lovering, S. J. Elledge, M. Pagano, and J. W. Harper, "Systematic analysis and nomenclature of mammalian F-box proteins, " Genes & Development, vol. 18, no. 21, pp. 2573-2580, 2004.
13. D. Frescas and M. Pagano, "Deregulated proteolysis by the Fbox proteins SKP2 and -TrCP: tipping the scales of cancer, " Nature Reviews Cancer, vol. 8, no. 6, pp. 438-449, 2008.
14. S. Y. Fuchs, V. S. Spiegelman, and K. G. S. Kumar, "The many faces of -TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer, " Oncogene, vol. 23, no. 11, pp. 2028-2036, 2004.
15. Y. Tan, O. Sangfelt, and C. Spruck, "The Fbxw7/hCdc4 tumor suppressor in human cancer, " Cancer Letters, vol. 271, no. 1, pp. 1-12, 2008.
16. R. K. Mallampalli, T. A. Coon, J. R. Glasser et al. , "Targeting F box protein Fbxo3 to control cytokine-driven inflammation, " Journal of Immunology, vol. 191, no. 10, pp. 5247-5255, 2013.
17. N. M. Weathington and R. K. Mallampalli, "Emerging therapies targeting the ubiquitin proteasome systemin cancer, " Journal of Clinical Investigation, vol. 124, no. 1, pp. 6-12, 2014.
18. B. B. Chen and R. K. Mallampalli, "Masking of a nuclear signal motif by monoubiquitination leads to mislocalization and degradation of the regulatory enzyme cytidylyltransferase, " Molecular and Cellular Biology, vol. 29, no. 11, pp. 3062-3075, 2009.
19. M. Sauane, R. V. Gopalkrishnan, I. Lebedeva et al. , "Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways, " Journal of Cellular Physiology, vol. 196, no. 2, pp. 334-345, 2003.
20. L. Chang and M. Karin, "Mammalian MAP kinase signalling cascades, " Nature, vol. 410, no. 6824, pp. 37-40, 2001.
21. R. Nunez, "DNA measurement and cell cycle analysis by flow cytometry, " Current Issues inMolecular Biology, vol. 3, no. 3, pp. 67-70, 2001.
22. K. G. S. Kumar, J. J. Krolewski, and S. Y. Fuchs, "Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor, " Journal of Biological Chemistry, vol. 279, no. 45, pp. 46614-46620, 2004.
23. H. Jiang, Y. Lu, L. Yuan, and J. Liu, "Regulationof interleukin-10 receptor ubiquitination and stability by beta-TrCP-containing ubiquitin E3 ligase, " PLoS ONE, vol. 6, no. 11, Article ID e27464, 2011.
24. C. Sutherland, "What are the bona fide GSK3 substrates?" International Journal of Alzheimer's Disease, vol. 2011, Article ID 505607, 23 pages, 2011.
25. A. W. Lau, Y. Liu, A. E. Tron, H. Inuzuka, andW. Wei, "The role of FBXWsubfamily of F-box proteins in tumorigenesis, " in SCF and APC E3 Ubiquitin Ligases in Tumorigenesis, SpringerBriefs in Cancer Research, pp. 15-45, Springer, New York, NY, USA, 2014.
26. M. Welcker and B. E. Clurman, "FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation, " Nature Reviews Cancer, vol. 8, no. 2, pp. 83-93, 2008.
27. S. Brand, F. Beigel, T. Olszak et al. , "IL-22 is increased in active Crohn's disease andpromotes proinflammatorygene expression and intestinal epithelial cellmigration, "TheAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 4, pp. G827-G838, 2006.